#Artery Stenosis Drug Market trends
Explore tagged Tumblr posts
Text
Peripheral Vascular Devices Market is Estimated to Witness High Growth Owing to Rising Geriatric Population
Peripheral vascular devices are used for the treatment and diagnosis of peripheral artery diseases. These devices help in plaque removal, angioplasty and stenting which restore smooth blood flow to limbs. The rising prevalence of peripheral artery diseases due to diabetes, obesity and high blood pressure has fueled the demand for peripheral vascular devices. Peripheral vascular devices include angioplasty balloons, stents, catheters, arterial sheaths, guidewires and other devices. Technologically advanced devices with enhanced safety, efficacy and ease of installation have gained traction in the recent years.
The global peripheral vascular devices market is estimated to be valued at US$ 12.68 Bn in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2024 to 2031.
Key Takeaways Key players operating in the peripheral vascular devices are Abbott Laboratories, Boston Scientific Corporation, Angioscore, Emboline Inc., Becton Dickinson and Company, Cook Group Inc., Cordis Corporation, Covidien PLC, Edward Lifesciences Corporation, Medtronic Plc, St. Jude Medical, Bayer AG., Teleflex Medical, Koninklijke Philips N.V., Cardio Flow, Inc. Key players are focusing on new product launches, mergers and acquisitions to strengthen their market presence.
The rising geriatric population prone to peripheral artery diseases and growing preference for minimally invasive surgeries offer significant growth opportunities for players in the Peripheral Vascular Devices Market Size Furthermore, expanding healthcare infrastructure and increasing healthcare expenditure in emerging economies is also expected to fuel the adoption of peripheral vascular devices globally over the forecast period.
Market Drivers The rising geriatric population is one of the key drivers of the peripheral vascular devices market. According to the UN data, the world’s population aged 60 years and above is projected to double from 12% to 22% between 2015 and 2050. The elderly are more susceptible to developing peripheral artery diseases owing to reduced blood circulation and weakening of arteries with age. This is expected to significantly drive the demand for peripheral vascular devices over the next few years.
PEST Analysis
Political: Peripheral Vascular Devices Market Size And Trends are subject to extensive government regulations resulting from stringent FDA approvals for new products and procedures. Regulations impact product development timelines and costs.
Economic: Growth in the peripheral vascular devices market is driven by rising healthcare expenditure, growing elderly population suffering from peripheral vascular diseases, and favorable reimbursement policies for life-saving procedures.
Social: Increasing awareness about peripheral vascular diseases and availability of advanced treatment options encourage people to seek medical care. Sedentary lifestyles and obesity rates also contribute to the patient volumes.
Technological: Innovation leads to the development of novel drug-eluting, bioresorbable, and nano-technology based stents that reduce in-stent re-stenosis rates. Robotics, AI, and 3D printing are enhancing surgical precision and customization.
Market value concentration by geographical regions: North America accounts for the largest share of the overall peripheral vascular devices market in terms of value, owing to the high usage of advanced equipment, growing number of vascular surgeries, and supportive insurance system. Asia Pacific is expected to witness the fastest value growth over the forecast period, with expanding healthcare infrastructure and increasing medical tourism from other regions.
Fastest growing regional market: Asia Pacific peripheral vascular devices market exhibits immense growth potential attributed to the rising awareness, healthcare reforms, and willingness to adopt modern treatments. Factors like growing elderly population, increasing obesity prevalence, presence of contract manufacturers and emerging economies propel the regional market growth at a rapid rate. Get More Insights On, Peripheral Vascular Devices Market About Author: Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
#Peripheral Vascular Devices Market Size#Peripheral Vascular Devices Market Trends#Peripheral Vascular Devices Market Share#Peripheral Vascular Devices#Peripheral Vascular Devices Market
0 notes
Text
Artery Stenosis Drug Market Will Accelerate Rapidly with Top Influencing Key players | Pfizer Inc, Eli Lilly and Company, Bristol-Myers Squibb Company.
Artery Stenosis Drug Market is a narrowing of the arteries that supply oxygen rich blood to vital organs and tissues such as brain, kidney and limbs. The causes of Artery stenosis is the deposition of plaque (atherosclerosis) inside the artery wall which reduces blood flow to the vital organs and tissues. Mostly people suffering from artery stenosis have no symptoms until the artery becomes severely narrowed. Symptoms generally occur with a mini-stroke followed by dizziness, fainting and blurred vision.
Artery stenosis drug market is expected to grow with the substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. This rise in market value can be attributed to rising patient awareness regarding early detection, prevention, and treatment of strokes.
Get Sample Report at :
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-artery-stenosis-drug-market
Competitive Analysis: Global Artery Stenosis Drug Market
Few of the major competitors currently working in Global Artery Stenosis Drug Market are Abbott, GlaxoSmithKline plc, ALLERGAN, Novartis AG, Merck & Co., Inc, Sanofi, Pfizer Inc, Eli Lilly and Company, Bristol-Myers Squibb Company, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Baxter, Medtronic, Johnson & Johnson Services, Inc, Cook Group among others.
Key Pointers Covered in the Global Artery Stenosis Drug Market Trends and Forecast to 2026
Global Artery Stenosis Drug Market New Sales Volumes
Global Artery Stenosis Drug Market Replacement Sales Volumes
Global Artery Stenosis Drug Market Installed Base
Global Artery Stenosis Drug Market By Brands
Global Artery Stenosis Drug Market Size
Global Artery Stenosis Drug Market Procedure Volumes
Global Artery Stenosis Drug Market Product Price Analysis
Global Artery Stenosis Drug Market Healthcare Outcomes
Global Artery Stenosis Drug Market Cost of Care Analysis
Global Artery Stenosis Drug Market Regulatory Framework and Changes
Global Artery Stenosis Drug Market Prices and Reimbursement Analysis
Global Artery Stenosis Drug Market Shares in Different Regions
Recent Developments for Global Artery Stenosis Drug Market Competitors
Global Artery Stenosis Drug Market Upcoming Applications
Global Artery Stenosis Drug Market Innovators Study
Get Detailed TOC:
https://www.databridgemarketresearch.com/toc/?dbmr=global-artery-stenosis-drug-market
Key Developments in the Market:
In February 2019, M.A. MedAlliance SA received Breakthrough Device designation from the U.S FDA for selution, sirolimus, sustained limus release (SLR) drug-eluting balloon (DEB) catheter, to treat coronary disease. This designation will provide company with the priority review and assistance from the FDA regarding device development and its approval.
In October 2018, Johnson & Johnson Services, Inc received the U.S FDA approval for Xarelto (rivaroxaban), factor Xa (FXa) inhibitor for the treatment of chronic coronary or peripheral artery disease. This drug is specifically approved for reducing the risk of major cardiovascular disorders such as stroke and myocardial infarction in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Scope of the Artery Stenosis Drug Market
Global Artery Stenosis Drug Market By Indication Type (Carotid Artery Stenosis, Renal Artery Stenosis, Peripheral Artery Stenosis, Coronary Artery Stenosis and Others), Treatment (Medication and Surgery), Drugs (Atorvastatin, Fluvastatin, Heparin, Minoxidil, Aspirin and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2027
Artery stenosis drug market is expected to grow with the substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. This rise in market value can be attributed to rising patient awareness regarding early detection, prevention, and treatment of strokes.
Artery stenosis is a narrowing of the arteries that supply oxygen rich blood to vital organs and tissues such as brain, kidney and limbs. The causes of Artery stenosis is the deposition of plaque (atherosclerosis) inside the artery wall which reduces blood flow to the vital organs and tissues. Mostly people suffering from artery stenosis have no symptoms until the artery becomes severely narrowed. Symptoms generally occur with a mini-stroke followed by dizziness, fainting and blurred vision.
Speak to Author :
https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-artery-stenosis-drug-market
Key insights in the report:
Complete and distinct analysis of the market drivers and restraints
Key Market players involved in this industry
Detailed analysis of the Market Segmentation
Competitive analysis of the key players involved
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Browse Related Report Here:
North America Nasal Spray Market
Chronic Iron Overload Market
#Artery Stenosis Drug Market#Artery Stenosis Drug Market share#Artery Stenosis Drug Market size#Artery Stenosis Drug Market trends#Artery Stenosis Drug Market news#Artery Stenosis Drug Market report#Artery Stenosis Drug Market growth
0 notes
Photo
Artery Stenosis Drug Market - Industry Trends and Forecast to 2027
Artery stenosis drug market is expected to grow with the substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. This rise in market value can be attributed to rising patient awareness regarding early detection, prevention, and treatment of strokes.
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-artery-stenosis-drug-market
#Artery Stenosis Drug Market#Artery Stenosis Drug Market share#Artery Stenosis Drug Market size#Artery Stenosis Drug Market trends#Artery Stenosis Drug Market news#Artery Stenosis Drug Market report#Artery Stenosis Drug Market growth
0 notes
Link
0 notes
Text
Vascular Access Device Market Size Historical Growth, Analysis, Opportunities and Forecast
The global Vascular Access Device Market size is expected to reach USD 7.72 billion by 2027 according to a new study by Polaris Market Research. The report “Vascular Access Device Market Share, Size, Trends, Industry Analysis Report, By Type (Central Vascular Access Devices {Peripherally Inserted Central Catheters, Tunneled Catheters, Percutaneous Non-Tunneled Catheters, and Implanted Ports} Peripheral Vascular Access Devices {Short Midline Catheters, Midclavicular Catheters, and Winged Steel Needles}; and Other Accessories); By Application (Fluid and Nutrition Administration, Drug Administration, Blood Transfusion, and Diagnostics & Testing); By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Other End Users); By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Devices that are used to access venous irrespective of their location are known as vascular access devices (VAD). The different types of VADs include centrally inserted central catheter (CICC), peripheral intravenous catheters, and peripheral central catheter (PICC), and other implanted venous ports. VADs are inserted into peripheral or central vessels for the administration of fluids, antibiotics, parenteral nutrition, and blood sampling.
Download Sample Copy : https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market/request-for-sample
The selection VADs is extremely important in treating any particular medical condition to reduce the risk of catheter bound infections. Healthcare practitioners should be aware of selecting VADs with least number of the lumen and small French size to minimize infections and thrombotic complications. For instance, people suffering with chronic kidney disorder seeking central venous access should avoid placement PICC and CICC to avoid the complication of venous stenosis and deep vein thrombosis.
The factors responsible for the growth of global market are rising cases of chronic kidney disorder (CKD), increasing cases of PAD and CAD among geriatrics, and preference of patients towards minimal invasive surgeries is contributing to the worldwide demand of vascular devices. According to the statistics published by Center for Disease Control and Prevention (CDC), in 2019, more than 8.5 million U.S. citizens were suffering with peripheral artery disease (PAD). People with PAD are more susceptible to develop coronary artery disease, which could ultimately lead to strokes or cardiac arrhythmias.
Get Discount Copy @ https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market/request-for-discount-pricing
Market participants such as Smiths Medical, Inc., Becton Dickinson and Company, C.R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen Ag, Bluegrass Vascular Technologies, Edwards Lifesciences Corporation, Angiodynamics Inc., Biomerics, Terumo Corporation, Romsons Scientific & Surgical Pvt. Ltd, Nipro Medical Corporation, Ameco Medical, and Prodi med are some of the key players operating in the concerned market. These players in the industry possess a significant share in the global market. However, these significant players face competition from local manufacturers in several countries. They adopt competitive pricing to consolidate their market share. These vendors provide cost-effective equipment with limited features and functionalities.
Read More : https://www.medgadget.com/2020/06/vascular-access-device-market-size-worth-7-72-billion-by-2027-cagr-7-7-exclusive-study-by-polaris-market-research.html
0 notes
Text
BIO-ENGINEERED STENT MARKET ANALYSIS
Bio-engineered Stent Market, by Application Type (Coronary Artery Disease, Peripheral Arterial Disease, Carotid Artery Disease, Renal Artery Stenosis, Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Others), by Product Type (Drug-eluting Stents, Bioabsorbable Stents, and Drug-eluting Balloons), by Mode of Delivery (Balloon-expandable Stents and Self-expanding Stents), by Material Type (Metal-based and Polymer-based), by End User (Hospitals & Cardiac Centers and Ambulatory Surgical Centers, Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights and Forecast to 2026
Bio-engineered stents consist of short narrow metal or plastic tube, which is used to treat blocked arteries. It is used by patients who are suffering from different types of cardiovascular diseases such as coronary heart disease and ischemic heart disease. Different types of bio-engineered stent are available in market for various diseases such as coronary artery disease, peripheral arterial disease, carotid artery disease, renal artery stenosis, abdominal aortic aneurysm, thoracic aortic aneurysm among others.
Market Dynamics
Increasing prevalence of renal diseases is a major factor driving bio-engineered stents market growth. According to American Heart Association Council, in 2015, cardiovascular disease was the leading cause of death worldwide, accounting for over 17.9 million deaths annually and this number is expected to increase to over 23.6 million by 2030. According to the same source, cardiovascular diseases accounted for around 836,546 deaths in the U.S. in 2015, which accounted for around 1 in every 3 deaths.
Moreover, key players in the market are focused on adopting various strategies such as new Product Type launch and approvals and partnerships and collaborations to increase their foothold in the market. For instance, in May 2017, Medtronic plc., received the U.S. Food and Drug Administration (FDA) approval and Resolute Onyx, 4.5 MM and 5 mm sizes Drug-Eluting Stent. This device has proven clinical performance and superior deliverability of the Resolute Integrity. This device is intended to treat people with coronary artery disease in the U.S.
However, availability of alternatives for the treatment of cardiac diseases, Product Type recalls and failure, and stringent regulations for Product Type approvals are expected to hinder the market growth. For instance in November 2017, Abbott recall Class 1 Device Recall Absorb Bioresorbable Vascular Scaffold (BVS) System, an absorbable coronary drug-eluting stent due to elevated rates of major adverse events, specifically, myocardial infraction and scaffold thrombosis when compared to patients treated with the Xience metallic drug eluting stent.
Key features of the study:
This report provides in-depth analysis of the bio-engineered stents market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global bio-engineered stents market based on the following parameters – company overview, financial performance, Product Type portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Medtronic, plc., Boston Scientific Corporation, Abbott Laboratories, Biotronik SE & Co. KG, B. Braun Melsungen AG, Terumo Corporation, MicroPort Scientific Corporation, Stentys Sao, Meril Life Sciences Pvt. Ltd, Vascular Concepts, W. L. Gore and Associates, C. R. Bard, Endologix, Inc., Lombard Medical Technologies, Translumina GmbH, and Jotec GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global Bio-engineered stents market report caters to various stakeholders in this industry including investors, suppliers, Product Type manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the bio-engineered stents market
Detailed Segmentation:
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting Balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
U.S.
Canada
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
Brazil
Mexico
Argentina
Rest of Latin America
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
GCC
Israel
Rest of Middle East
Coronary artery disease
Peripheral arterial disease
Carotid Artery Disease
Renal Artery Stenosis
Abdominal Aortic Aneurysm
Thoracic Aortic Aneurysm
Others
Drug-eluting Stents
Bioabsorbable Stents
Drug-eluting balloons
Balloon-expandable Stents
Self-expanding Stents
Metal-based
Polymer-based
Hospitals & Cardiac Centers
Ambulatory Surgical Centers
Others
South Africa
Central Africa
North Africa
Company Overview
Product Type Portfolio
Financial Performance
Key Highlights
Market Strategies
“*” marked represents similar segmentation in other categories in the respective section.
Request the sample copy of here:
https://www.coherentmarketinsights.com/insight/request-sample/2484
Download the PDF Brochure here:
https://www.coherentmarketinsights.com/insight/request-pdf/2484
Buy now the market research report here:
https://www.coherentmarketinsights.com/insight/buy-now/2484
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis
Explore CMI Services here
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email: [email protected]
Source:
https://www.coherentmarketinsights.com/market-insight/bio-engineered-stent-market-2484
0 notes
Text
Transcatheter Heart Valve Market Analysis (2020-2027)
Transcatheter heart valve implantation is a minimally-invasive procedure to repair damaged heart valves with bioprosthetic valves for treatment of valvular heart disease (VHD), namely aortic stenosis and mitral regurgitation. It is an alternative approach to conventional open heart surgery and is especially recommended for extremely high risk patients.
Statistics:
The global transcatheter heart valve market is estimated to account for US$ 7,642.7 Mn in terms of value by the end of 2027.
Global Transcatheter Heart Valve Market: Drivers
Increasing prevalence of VHD is a major factor boosting growth of the global transcatheter heart valve market over the forecast period. For instance, according to the study, ‘Epidemiology and Trends of Aortic Stenosis Mortality in the United States (1999-2016)’, published in Journal of the American College of Cardiology in March 2019, aortic stenosis was associated with a mortality rate of 106.3 per 1 million persons, with highest mortality rate in non-Hispanic whites followed by Hispanics, and non-Hispanic blacks. Moreover, the study noticed increase in age-adjusted mortality between the period.
Therefore, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.
North America region held dominant position in the global transcatheter heart valve market in 2019, accounting for 53.6% share in terms of value, followed by Europe.
Figure 1. Global Transcatheter Heart Valve Market Share (%), by Region, 2019
Global Transcatheter Heart Valve Market: Restraints
High cost of transcatheter heart valves is expected to hinder growth of the global transcatheter heart valve market. For instance, the average cost of transcatheter aortic valve replacement (TAVR) devices is US$ 32,000 as compared to US$ 4,000–US$ 7,000 for surgical aortic valve replacement (SAVR) devices.
Moreover, TAVR is associated with some risks and complications such as artery damage due to insertion of catheter that can lead to major bleeding, valve leakage, infection, kidney failure, heart attack, major stroke, and fatality during procedure.
Global Transcatheter Heart Valve Market: Opportunities
Players in the market can focus on development and launch of affordable TAVR products in order to enhance their share in emerging market such as India, China, and Brazil.
Moreover, there is rising concern about cerebrovascular events that can occur after TAVR, which are associated with increased mortality. Therefore, development of standardized definitions and assessments of neurological endpoints for TAVR and other cardiac interventions is also expected to offer lucrative growth opportunities for players in the market.
Transfemoral Approach segment in the global transcatheter heart valve market was valued at US$ 2,369.4 Mn in 2019 and is expected to reach US$ 6,814.2 Mn by 2025 at a CAGR of 14.1% during the forecast period.
Market Trends/Key Takeaways
Major hospitals are focused on adopting TAVR for the treatment of aortic stenosis. For instance, in January 2020, Chester County Hospital announced that TAVR will be available in a couple of months at appropriate patients at the hospital.
Several regulatory bodies are focused on extending the indications of transcatheter heart valves. For instance, in August 2019, the U.S. Food and Drug Administration approved an expanded indication for several transcatheter heart valves that include, Sapien 3, Sapien 3 Ultra, CoreValve Evolut R, and CoreValve Evolut PRO for patients with severe aortic valve stenosis.
Regulations:
U.S.
· In the U.S., FDA Center for Device and Radiological Health (FDA/CDRH) is responsible for regulation of medical devices
· TAVR is categorized by FDA/CDRH as a class III significant risk device, which requires demonstration of safety and effectiveness for approval as part of the premarket approval (PMA) process.
Global Transcatheter Heart Valve Market: Competitive Landscape
Major players operating in the global transcatheter heart valve market include, Edwards Lifesciences Corporation, Medtronic, Boston Scientific Corporation, Abbott, JenaValve Technology, SYMETIS, and Braile Biomedica.
Global Transcatheter Heart Valve Market: Key Developments
Major players in the market are focused on product approval and launch to expand their product portfolio. For instance, in January 2020, JenaValve Technology received the U.S. FDA’s breakthrough device designation for its pericardial TAVR device.
In November 2019, Edwards Lifesciences Corporation received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients diagnosed with aortic stenosis who are at low risk for open-heart surgery.
Request sample copy here :
https://www.coherentmarketinsights.com/insight/request-sample/3380
Request PDF brochure here:
https://www.coherentmarketinsights.com/insight/request-pdf/3380
Click here to buy: https://www.coherentmarketinsights.com/insight/buy-now/3380
CMI Services: https://www.coherentmarketinsights.com/services
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
· Customized Market Research Services
· Industry Analysis Services
· Business Consulting Services
· Market Intelligence Services
· Long term Engagement Model
· Country Specific Analysis
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email : [email protected]
Reference/Source: https://www.coherentmarketinsights.com/market-insight/transcatheter-heart-valve-market-3380
#CoherentMarketInsights#MarketAnalysis#Healthcare#FractionalFlowReserveMarketAnalysis#repairdamagedheartvalves#Marketresearch
0 notes
Text
TRANSCATHETER HEART VALVE MARKET ANALYSIS
Transcatheter heart valve implantation is a minimally-invasive procedure to repair damaged heart valves with bioprosthetic valves for treatment of valvular heart disease (VHD), namely aortic stenosis and mitral regurgitation. It is an alternative approach to conventional open heart surgery and is especially recommended for extremely high risk patients.
Statistics:
The global transcatheter heart valve market is estimated to account for US$ 7,642.7 Mn in terms of value by the end of 2027.
Global Transcatheter Heart Valve Market: Drivers
Increasing prevalence of VHD is a major factor boosting growth of the global transcatheter heart valve market over the forecast period. For instance, according to the study, ‘Epidemiology and Trends of Aortic Stenosis Mortality in the United States (1999-2016)’, published in Journal of the American College of Cardiology in March 2019, aortic stenosis was associated with a mortality rate of 106.3 per 1 million persons, with highest mortality rate in non-Hispanic whites followed by Hispanics, and non-Hispanic blacks. Moreover, the study noticed increase in age-adjusted mortality between the period.
Therefore, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.
North America region held dominant position in the global transcatheter heart valve market in 2019, accounting for 53.6% share in terms of value, followed by Europe.
Figure 1. Global Transcatheter Heart Valve Market Share (%), by Region, 2019
Global Transcatheter Heart Valve Market: Restraints
High cost of transcatheter heart valves is expected to hinder growth of the global transcatheter heart valve market. For instance, the average cost of transcatheter aortic valve replacement (TAVR) devices is US$ 32,000 as compared to US$ 4,000–US$ 7,000 for surgical aortic valve replacement (SAVR) devices.
Moreover, TAVR is associated with some risks and complications such as artery damage due to insertion of catheter that can lead to major bleeding, valve leakage, infection, kidney failure, heart attack, major stroke, and fatality during procedure.
Global Transcatheter Heart Valve Market: Opportunities
Players in the market can focus on development and launch of affordable TAVR products in order to enhance their share in emerging market such as India, China, and Brazil.
Moreover, there is rising concern about cerebrovascular events that can occur after TAVR, which are associated with increased mortality. Therefore, development of standardized definitions and assessments of neurological endpoints for TAVR and other cardiac interventions is also expected to offer lucrative growth opportunities for players in the market.
Transfemoral Approach segment in the global transcatheter heart valve market was valued at US$ 2,369.4 Mn in 2019 and is expected to reach US$ 6,814.2 Mn by 2025 at a CAGR of 14.1% during the forecast period.
Market Trends/Key Takeaways
Major hospitals are focused on adopting TAVR for the treatment of aortic stenosis. For instance, in January 2020, Chester County Hospital announced that TAVR will be available in a couple of months at appropriate patients at the hospital.
Several regulatory bodies are focused on extending the indications of transcatheter heart valves. For instance, in August 2019, the U.S. Food and Drug Administration approved an expanded indication for several transcatheter heart valves that include, Sapien 3, Sapien 3 Ultra, CoreValve Evolut R, and CoreValve Evolut PRO for patients with severe aortic valve stenosis.
Regulations:
U.S.
In the U.S., FDA Center for Device and Radiological Health (FDA/CDRH) is responsible for regulation of medical devices
TAVR is categorized by FDA/CDRH as a class III significant risk device, which requires demonstration of safety and effectiveness for approval as part of the premarket approval (PMA) process.
Global Transcatheter Heart Valve Market: Competitive Landscape
Major players operating in the global transcatheter heart valve market include, Edwards Lifesciences Corporation, Medtronic, Boston Scientific Corporation, Abbott, JenaValve Technology, SYMETIS, and Braile Biomedica.
Global Transcatheter Heart Valve Market: Key Developments
Major players in the market are focused on product approval and launch to expand their product portfolio. For instance, in January 2020, JenaValve Technology received the U.S. FDA’s breakthrough device designation for its pericardial TAVR device.
In November 2019, Edwards Lifesciences Corporation received CE Mark to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients diagnosed with aortic stenosis who are at low risk for open-heart surgery.
About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah
Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: [email protected]
#TRANSCATHETER HEART VALVE MARKET ANALYSIS#valvular heart disease#transcatherer heart valve#heart disease
0 notes
Text
India coronary stents Market to Surpass US$ 2,049.9 Million by 2027.
Summary:India coronary stents to lead the market during forecast period with market valuation of US$ 671.3 Mn in 2018.
Description:
A cardiac stent is employed to treat narrowed or blocked coronary arteries. It also can be wont to improve blood flow immediately following a attack .Cardiac stents are expandable coils made from metal mesh.Coronary stents (CS) are expandable tubular metallic devices which are introduced into the coronary arteries that demonstrate stenosis thanks to an underlying atherosclerosis disease. This revascularization procedure is termed as a percutaneous coronary intervention (PCI) or coronary angioplasty with stent placement.
Key Trends:
Key trends in the market include The demand for coronary stents has been outbreaks, which has encouraged medical devices and equipment manufacturers to focus on creating affordable and sustainable products to garner a competitive edge over rivals.
The market witnessed 80% decrease in prices of coronary stents. However, in April 2019, National Pharmaceutical Pricing Authority (NPPA) approved hike in prices of cardiac stents by 4.2% in-line with the wholesale price level (WPI) of 2018.The new stent could further assist interventional cardiologists in treating arteria coronaria diseases more effectively.
Request for Sample PDF copy @ https://www.coherentmarketinsights.com/insight/request-pdf/3484
The goal of pricing control is to increase demand for coronary stents.However,The National Pharmaceutical Pricing Authority of India (NPPA), for instance, reduced the prices of DES in February 2018.
Key Market Takeaways:
· Growing prevalence of arteria coronaria disease, which is one among the main causes of mortality, along side higher prices of stents are crucial factors that have compelled various regulatory agencies to spice up the supply of affordable coronary stents across their respective countries.
· India coronary stents market is estimated to account for US$ 671.3 Mn in terms of value in 2018 and is expected to reach US$ 2,049.9 Mn by the end of 2027.
Competitive Landscape
Major players operating in India coronary stents market include, Abbott Laboratories, Medtronic, Inc., Biosensors Inc., Terumo Corporation, and Boston Scientific Inc.
Buy this Research Report @https://www.coherentmarketinsights.com/insight/buy-now/3484
Geographical Analysis:
Asia pacific is anticipated to point out rapid climb during the forecast period due to the improved supply chain of coronary stents across pharmacies across hospitals within the region, especially in developing regions of India and China.
Asia-Pacific and LAMEA collectively accounted for one-fourth of the entire coronary stents market and are expected to continue this trend thanks to increase in stents development, specifically in China, India, and therefore the other developing countries. Rise in geriatric population is that the main reason for the expansion of coronary stents market within the Indian region
Related Topics:
HEALTHCARE CONTRACT RESEARCH OUTSOURCING MARKET
Healthcare Contract Research Outsourcing is conducted by pharmaceutical and medical device sectors for development of new drugs and medical devices. Clinical trials form the key part of pharmaceutical drug and medical device development and in the current scenario clinical trials are conducted across multiple locations in various geographies. Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.
Read more @ https://www.coherentmarketinsights.com/market-insight/healthcare-contract-research-outsourcing-market-3788
ANDROGEN REPLACEMENT THERAPY MARKET
Androgen replacement therapy (ART), often referred to as testosterone replacement therapy (TRT), is a form of hormone therapy, in which androgens, often testosterone, are replaced. ART is often prescribed to counter the effects of male hypogonadism. It typically involves the administration of testosterone through injections, skin creams, patches, gels, or subcutaneous pellets. Testosterone replacement therapy is a promising technology for improving symptoms of hypogonadism and to raise the testosterone level.
Read more @ https://www.coherentmarketinsights.com/market-insight/androgen-replacement-therapy-market-3787
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
Customized Market Research Services
Industry Analysis Services
Business Consulting Services
Market Intelligence Services
Long term Engagement Model
Country Specific Analysis
Contact Us:
Mr. Shah
Coherent Market Insights Pvt.Ltd.
Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email: [email protected]
Reference:
Coherent Market insight
#cardiac stent#coronary stents#coronary angioplasty#Healthcare#coherent market insights#market analysis#market research
0 notes
Text
Vascular Access Device Market Size To Acquire Increasing Research Investments By 2027
The global Vascular Access Device Market size is expected to reach USD 7.72 billion by 2027 according to a new study by Polaris Market Research. The report “Vascular Access Device Market Share, Size, Trends, Industry Analysis Report, By Type (Central Vascular Access Devices {Peripherally Inserted Central Catheters, Tunneled Catheters, Percutaneous Non-Tunneled Catheters, and Implanted Ports} Peripheral Vascular Access Devices {Short Midline Catheters, Midclavicular Catheters, and Winged Steel Needles}; and Other Accessories); By Application (Fluid and Nutrition Administration, Drug Administration, Blood Transfusion, and Diagnostics & Testing); By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Other End Users); By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Devices that are used to access venous irrespective of their location are known as vascular access devices (VAD). The different types of VADs include centrally inserted central catheter (CICC), peripheral intravenous catheters, and peripheral central catheter (PICC), and other implanted venous ports. VADs are inserted into peripheral or central vessels for the administration of fluids, antibiotics, parenteral nutrition, and blood sampling.
Request for a sample copy of this research report @ https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market/request-for-sample
The selection VADs is extremely important in treating any particular medical condition to reduce the risk of catheter bound infections. Healthcare practitioners should be aware of selecting VADs with least number of the lumen and small French size to minimize infections and thrombotic complications. For instance, people suffering with chronic kidney disorder seeking central venous access should avoid placement PICC and CICC to avoid the complication of venous stenosis and deep vein thrombosis.
The factors responsible for the growth of global market are rising cases of chronic kidney disorder (CKD), increasing cases of PAD and CAD among geriatrics, and preference of patients towards minimal invasive surgeries is contributing to the worldwide demand of vascular devices. According to the statistics published by Center for Disease Control and Prevention (CDC), in 2019, more than 8.5 million U.S. citizens were suffering with peripheral artery disease (PAD). People with PAD are more susceptible to develop coronary artery disease, which could ultimately lead to strokes or cardiac arrhythmias.
Market participants such as Smiths Medical, Inc., Becton Dickinson and Company, C.R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen Ag, Bluegrass Vascular Technologies, Edwards Lifesciences Corporation, Angiodynamics Inc., Biomerics, Terumo Corporation, Romsons Scientific & Surgical Pvt. Ltd, Nipro Medical Corporation, Ameco Medical, and Prodi med are some of the key players operating in the concerned market. These players in the industry possess a significant share in the global market. However, these significant players face competition from local manufacturers in several countries. They adopt competitive pricing to consolidate their market share. These vendors provide cost-effective equipment with limited features and functionalities.
Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/vascular-access-device-market
Polaris Market research has segmented the Vascular Access Device Market report on the basis of type, application, end-use and region
Vascular Access Devices Type Outlook (Revenue – USD Million, 2016 – 2027)
Peripherally inserted central catheters (PICC)
Tunneled catheters
Non tunneled catheters
Implanted ports
Midline catheters
Midclavicular catheters
Winged steel needles
Vascular Access Devices Application Outlook (Revenue – USD Million, 2016 – 2027)
Drug administration
Fluid and nutrition administration
Blood transfusion
Diagnostics & testing
Vascular Access Devices End-Use Outlook (Revenue – USD Million, 2016 – 2027)
Hospitals
Clinics
Ambulatory care centers
Other end users
Vascular Access Devices Regional Outlook (Revenue – USD Million, 2016 – 2027)
U.S.
Canada
France
Germany
UK
Italy
Belgium
Spain
Austria
China
India
Japan
Malaysia
Australia
Indonesia
Mexico
Brazil
Argentina
UAE
Saudi Arabia
Israel
South Africa
Purchase This Report @: https://www.polarismarketresearch.com/checkouts/6481
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
Web: www.polarismarketresearch.com
#Vascular Access Device Market#Vascular Access Device Market share#Vascular Access Device Market size
0 notes
Text
Coronary Stent Market Estimation, Global Share, Industry Outlook, Price Trend, Growth Opportunity and Top Regional Forecast 2030
The Coronary Stent Market - Global Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, business strategies, research & development activities, production and consumption, supply chain analysis, competitive landscape, and market composition analysis. National Center for Biotechnology Information, U.S. National Library of Medicine defines coronary stents as – “Coronary stents (CS) are expandable tubular metallic devices which are introduced into the coronary arteries that demonstrate stenosis due to an underlying atherosclerosis disease.” This revascularization is known as percutaneous coronary intervention (PCI) or coronary angioplasty with stent placement. The prevalence of cardiovascular diseases is increasing globally with a death toll of 17.9 million people or 31% of the total deaths annually. Coronary stents helps in compressing atherosclerotic plaque against the vascular walls and restores blood flow. This has increased the demand for coronary stents to treat the coronary blockages. The global coronary stent market is anticipated to expand at a CAGR of 7.0% during next decade.
Request For The Sample Report Here - https://www.insightslice.com/request-sample/292
Fueled by adoption in treatment of multiple interventional cardiac diseases, drug eluting stents to drive the market growthThe global coronary stents market is segmented based on type, mode of delivery, material, end use, and geography. Based on type, the global coronary stents market is segmented into bare metal stents, drug eluting stents, bio-absorbable stents, and drug eluting stents balloons. Among these, the drug eluting stents dominated the market in 2018 and is anticipated to expand at a prominent CAGR during the forecast owing to applications in treatment of diabetes, renal disease, percutaneous coronary intervention, ST-segment elevation myocardial infarction (STEMI), and others. The bio-absorbable stents are anticipated to be the fastest growing coronary stents during the forecast period owing to rising demand from percutaneous coronary intervention treatment.
Balloon expandable coronary stents to dominate market owing to high precision in placement offered by these stents
Based on mode of delivery, the market is segmented into balloon-expandable stents and self-expanding stents. The balloon expandable stents dominated the market in 2018 and is anticipated to grow at a steady rate during forecast period. The balloon expandable stents support high radial outward force that allows for high precision in placement of these stents, thereby increasing the adoption in treatment of multiple diseases. The self-expanding stents are anticipated to be the fastest growing coronary stents patency over balloon expandable stents.
Based on geography, the market is segmented into North America, South America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the market in 2018 owing to high prevalence of cardiac disorders, diabetes and other diseases. Based on the statistics from the U.S. Department of Health & Human Services, an average of US$ 219 Billion is spent annually on health care services, medicines, and lost productivity owing to death due to heart diseases. This is anticipated to be the major factor generating demand for coronary stents in North America. Asia Pacific coronary stent market is anticipated to witness prominent growth during the forecast period due to rising number of patients suffering from Coronary Artery Disease.
Major players dominating the global coronary stent market include Abbott Laboratories, Braun Medical Inc., Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Medical Technologies, Medtronic PLC, Terumo Corporation, and Translumina GmbH.
Click Here to Download Sample Report @ https://www.insightslice.com/request-sample/292
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting with an aim to provide end-to-end solutions. For more details please contact our research and consulting team at [email protected].
0 notes
Text
Artery Stenosis Drug Market Strategic Insights and key Business Influencing Factors | Major Players – Pfizer Inc, Eli Lilly and Company, Bristol-Myers Squibb Company.
Artery Stenosis Drug Market is a narrowing of the arteries that supply oxygen rich blood to vital organs and tissues such as brain, kidney and limbs. The causes of Artery stenosis is the deposition of plaque (atherosclerosis) inside the artery wall which reduces blood flow to the vital organs and tissues. Mostly people suffering from artery stenosis have no symptoms until the artery becomes severely narrowed. Symptoms generally occur with a mini-stroke followed by dizziness, fainting and blurred vision.
Artery stenosis drug market is expected to grow with the substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. This rise in market value can be attributed to rising patient awareness regarding early detection, prevention, and treatment of strokes.
Get Sample Report at :
https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-artery-stenosis-drug-market
Competitive Analysis: Global Artery Stenosis Drug Market
Few of the major competitors currently working in Global Artery Stenosis Drug Market are Abbott, GlaxoSmithKline plc, ALLERGAN, Novartis AG, Merck & Co., Inc, Sanofi, Pfizer Inc, Eli Lilly and Company, Bristol-Myers Squibb Company, CELGENE CORPORATION, Takeda Pharmaceutical Company Limited, AstraZeneca, F. Hoffmann-La Roche Ltd, Bayer AG, Baxter, Medtronic, Johnson & Johnson Services, Inc, Cook Group among others.
Key Pointers Covered in the Global Artery Stenosis Drug Market Trends and Forecast to 2026
Global Artery Stenosis Drug Market New Sales Volumes
Global Artery Stenosis Drug Market Replacement Sales Volumes
Global Artery Stenosis Drug Market Installed Base
Global Artery Stenosis Drug Market By Brands
Global Artery Stenosis Drug Market Size
Global Artery Stenosis Drug Market Procedure Volumes
Global Artery Stenosis Drug Market Product Price Analysis
Global Artery Stenosis Drug Market Healthcare Outcomes
Global Artery Stenosis Drug Market Cost of Care Analysis
Global Artery Stenosis Drug Market Regulatory Framework and Changes
Global Artery Stenosis Drug Market Prices and Reimbursement Analysis
Global Artery Stenosis Drug Market Shares in Different Regions
Recent Developments for Global Artery Stenosis Drug Market Competitors
Global Artery Stenosis Drug Market Upcoming Applications
Global Artery Stenosis Drug Market Innovators Study
Get Detailed TOC:
https://www.databridgemarketresearch.com/toc/?dbmr=global-artery-stenosis-drug-market
Key Developments in the Market:
In February 2019, M.A. MedAlliance SA received Breakthrough Device designation from the U.S FDA for selution, sirolimus, sustained limus release (SLR) drug-eluting balloon (DEB) catheter, to treat coronary disease. This designation will provide company with the priority review and assistance from the FDA regarding device development and its approval.
In October 2018, Johnson & Johnson Services, Inc received the U.S FDA approval for Xarelto (rivaroxaban), factor Xa (FXa) inhibitor for the treatment of chronic coronary or peripheral artery disease. This drug is specifically approved for reducing the risk of major cardiovascular disorders such as stroke and myocardial infarction in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Scope of the Artery Stenosis Drug Market
Global Artery Stenosis Drug Market By Indication Type (Carotid Artery Stenosis, Renal Artery Stenosis, Peripheral Artery Stenosis, Coronary Artery Stenosis and Others), Treatment (Medication and Surgery), Drugs (Atorvastatin, Fluvastatin, Heparin, Minoxidil, Aspirin and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2027
Artery stenosis drug market is expected to grow with the substantial CAGR in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. This rise in market value can be attributed to rising patient awareness regarding early detection, prevention, and treatment of strokes.
Artery stenosis is a narrowing of the arteries that supply oxygen rich blood to vital organs and tissues such as brain, kidney and limbs. The causes of Artery stenosis is the deposition of plaque (atherosclerosis) inside the artery wall which reduces blood flow to the vital organs and tissues. Mostly people suffering from artery stenosis have no symptoms until the artery becomes severely narrowed. Symptoms generally occur with a mini-stroke followed by dizziness, fainting and blurred vision.
Speak to Author :
https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-artery-stenosis-drug-market
Key insights in the report:
Complete and distinct analysis of the market drivers and restraints
Key Market players involved in this industry
Detailed analysis of the Market Segmentation
Competitive analysis of the key players involved
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Browse Related Report Here:
North America Nasal Spray Market
Chronic Iron Overload Market
#Artery Stenosis Drug Market#Artery Stenosis Drug Market share#Artery Stenosis Drug Market size#Artery Stenosis Drug Market trends#Artery Stenosis Drug Market news#Artery Stenosis Drug Market report#Artery Stenosis Drug Market growth#Artery Stenosis Drug Market forecast
0 notes
Text
Market Research Reports, Analysis, Trends and Forecast
Global Hydrogen Breath Test Analyzer Market is estimated to value over USD 37 Million by 2029 end and register a CAGR of over 3.5% during the forecast period, 2019 to 2029.
Global Actinic Keratosis Treatment Market is calculated to value over USD 8.5 Billion by 2029 end and register a CAGR of over 4% from 2019 to 2029
Actinic keratosis is mainly observed in regions with a thin ozone layer as it is caused by prolonged exposure to dangerous UV rays which can result into squamous cell carcinoma. It is mainly observed in men and around 20% of patients with injuries from actinic keratosis create dangerous squamous cell carcinoma.
The Intravitreal (IVT) injectables market is poised to value over USD 5 billion by 2029 end.
Intravitreal (IVT) injectables are immensely prevalent among eye specialists. Anti–vascular endothelial growth factor (anti-VEGF) drugs are primarily used for treating macular degeneration, retinal vein occlusion, diabetic retinopathy and others. Rising prevalence of these diseases has expanded the anti-VEGF market assisting the growth of global IVT market.
Atherectomy Devices Market is estimated to value over USD 2.4 Billion by 2029 end and register a CAGR of over 6.5% during the forecast period 2019 to 2029
A growing preference for non-invasive procedures and an increasing prevalence of target diseases are some of the crucial aspects that drive the market. Furthermore, an increase in the geriatric population, the rising number of peripheral artery diseases (PAD) patients propel market growth. However, lack of skilled surgeons who can handle such non-invasive procedures can impede the market growth significantly.
The spinal stenosis implants market is calculated to register a CAGR of over 5.8% during the forecast period of 2019 to 2029. Spinal stenosis, which is the irregular narrowing of the spinal canal, is prominently observed in elderly patients. Some of its symptoms are numbness in legs, lower back pain and problem in balancing the body. A rise in the geriatric population is the key factor responsible for substantial market growth.
lateral flow assay market envisioned to value over US$ 9.7 Billion by 2029 end and register a CAGR of over 6.9% from 2019 to 2029.
Lateral flow assay is used to ratify pathogens or biomarkers in animals and humans. It's mostly used in human health and in medical diagnostics for laboratory use and home testing. Increase in disposable income and rising geriatric population are expected to fuel the growth of the market. Increase demand for home pregnancy tests is also boosting the growth of the market.
Neurovascular thrombectomy devices market value over USD 3 billion by 2029 end and register a CAGR of over 6.6% from 2019 to 2029.
Neurovascular thrombectomy devices are mainly employed in the arteries, veins, and capillaries to diffuse blood clots while causing minimal damage and blood loss. Diseases such as acute myocardial infarction, peripheral arterial diseases, deep vein thrombosis, pulmonary embolism, and neurovascular thrombosis conditions.
Injectable nanomedicines market to value over USD 400 Million by 2029 end and register a CAGR of over 8% from 2019 to 2029.
Substantial research and advancements in technology for drug development have given a significant boost in the global injectable nanomedicines market. Globally, the increase in use of liposomal drugs and growing patient population has fueled demand for injectable nanomedicines. Developing application of nanomedicines in the medical sector and therapeutics is further augmenting the demand of the global market.
Sleeping Aids Market is estimated to value over USD 115 Billion by 2029 end and register a CAGR of over 6.5% during the forecast period 2019 to 2029. Stressful lifestyles have reduced the amount of sleeping time an average person needs resulting in sleep disorders like insomnia, sleep apnea and mental disorders like depression and nervous breakdown. These are some of the crucial factors responsible for the significant growth of the sleep aids market globally.
The Triple-negative breast cancer treatment market is forecasted to value over US$ 820Million by 2029 end and register a CAGR of over 4.5% from 2019 to 2029. Triple-negative breast cancer is a type of cancer that does not have any receptors for hormones progesterone and estrogen. Triple-negative breast cancer does not respond to hormonal therapy and requires combines surgery.
Immune checkpoint inhibitors market value over USD 26 Billion by 2029 end and register a CAGR of over 13.6% from 2019 to 2029.
Immune checkpoint inhibitors are drugs used in advanced-stage cancers. These drugs work on the immunity of the body and the mechanism is to develop the patient’s body immunity to recognise, fight and annihilate the disease-causing bacteria or virus. Unlike other therapies, instead of attacking the tumour, this trains the body and it’s immunity to fight and protect the body from ailments.
Elder Care Services Market is estimated to value over USD 2.1 Billion by 2029 end and register a CAGR of over 6.3% during the forecast period 2019 to 2029. A rising number of geriatric patient population suffering from disabilities is one of the primary influential factors that drive the global elder care services market. Additionally, government-supported agencies, organizations associated with non-profit hospitals and independent charitable groups play a crucial role in the sustainability of the elder care services market.
Insomnia treatment market to value over USD 5.8 Billion by 2029 end and register a CAGR of over 5.2% from 2019 to 2029.
The growing cases of insomnia worldwide due to rising stress levels has led to the growth of this market. With rising geriatric population coupled with awareness about numerous therapies and treatments in the market, support and propel the market’s growth.
Robotic surgery system market to value over USD 6 Billion by 2029 end and register a CAGR of over 10% from 2019 to 2029.
Robotic surgery systems are an evolvement of medical sciences due to advancements in technology. Complex procedures are carried out with more accuracy, attention to detail and flexibility thus making it the preferable alternative over conventional traditional methods.
Feminine hygiene products market to value over USD 37.5 Billion by 2029 end and register a CAGR of over 9% from 2019 to 2029.
Major factors contributing to the robust growth of the global feminine hygiene products market are increased awareness about hygiene and sanitization and increasing purchasing power due to a rise in the disposable income. Rising awareness and environmental concern have opened up new avenues in the market for manufacturers to venture into and pursue. Thus the market for cloth sanitary pads and pads made from organic materials & biodegradable products witnesses high demand. This a fairly untapped sector and gives manufacturers to garner revenue through innovation and sale of premium products.
Breast implants market to value over USD 2.4 Billion by 2029 end and register a CAGR of over 6% from 2019 to 2029.
Mounting consciousness about physical appearance as well as technological advancements has helped the global breast implant market to grow. Breast implants are employed to augment the shape and size of breasts. Due to soaring innovations, the next-generation of breast implants are highly sought after due to their lightweight nature as compared to the traditional breast implants.
Lithotripsy Devices Market is assessed to value over US$ 1.9 Billion by 2029 and register a CAGR of over 4.3% from 2019 to 2029. Lithotripsy is the medical process of breaking down of kidney stones present in the kidney and other organs such as liver or gallbladder. Kidney stones, in general exit the body through urination but at times the body cannot pass large stones and it could cause severe pain, urinary tract infections, and bleeding. Therefore, breaking stones is necessary. After the breaking down of stones, the tiny pieces of stones exit the body through the urine.
Histopathology testing equipment market is envisioned to value over US$ 8 Billion by 2029 end and register a CAGR of over 4% from 2019 to 2029. Histopathology is the perusal of tissues from the body with the help of a microscope and the signs and characteristics of the disease can be spotted. The histopathology testing equipment tools are utilized for the perusal of tissues and preparing samples.
Syringes and cannulas market is envisioned to value over US$ 24.5 Billion by 2029 end and register a CAGR of over 4% from 2019 to 2029.
Rising surgeries alongside a growing pool of patients are accelerating the growth of the market. Since the healthcare industry requires syringes and cannulas in bulk, multiple local manufacturers have appeared to fulfil the bulk supply with affordable rates. This has inflated the size of the market.
Fetal and Neonatal Care Equipment Market is estimated to value over USD 9 Billion by 2029 end and register a CAGR of over 5% during the forecast period 2019 to 2029.
There has been a rapid rise in the birth rate worldwide. Additionally, there has been an increase in the number of premature births which increases demand for devices that can be utilized to reduce the fetal mortality rate. Increasing awareness regarding neonatal infant care is an integral factor which can assist the market to grow globally.
Airway or Lung Stents Market is estimated to value over USD 125 Million by 2029 end and register a CAGR of over 6.2% during the forecast period 2019 to 2029.
Airway or lung stent is inserted into an airway to replace the damaged one to ensure that the lungs function normally. The lung stent market is gaining significant traction owing to a rise in the geriatric population and the rapid adoption of lung stents in order to treat various chronic lung diseases.
Hemato Oncology Testing Market is estimated to value over USD 4.6 billion by 2029 end and register a CAGR of over 13.8% during the forecast period 2019 to 2029.
The type of product and service, the global hemato oncology market is bifurcated into services segment and assay kits segment. Based on the type of cancer, the market is categorised as leukaemia, acute myeloid leukaemia, acute lymphocytic leukaemia, lymphoma, non-hodgkin lymphoma, hodgkin lymphoma and others. As leukaemia patients require continuous monitoring and considering the ever-increasing number of leukaemia cases worldwide, this segment is anticipated to dominate the market during the forecast period.
Track and Trace Solutions Market is estimated to value over USD 4.5 billion by 2029 end and register a CAGR of over 14% during the forecast period 2019 to 2029.
Tack and trace solutions are implemented to monitor supply chains by major biopharmaceutical and pharmaceutical companies in order to curb down drug counterfeiting. Drug counterfeiting ranges from something relatively harmless as misleading medication with an intent to duplicate an authentic and approved product to the dangerous practice of selling medication consisting of an excess or insufficient amount of active ingredient. But using track and trace solutions, this obstacle can be eliminated to a very large extent.
0 notes
Link
0 notes
Text
Structural Heart Devices Market To Grow Like Never Before By 2026
Structural heart diseases refer to cardiac defects, which are congenital (by birth) in nature and also includes the abnormalities developed in valves and vessels of the heart caused by wear or tear due to some disease. Structural heart diseases is a non-coronary abnormality of heart, which does not affect the blood vessels in the heart. Common structural heart condition includes atrial septal defect, patent foramen oval, ventricular septal defect, paravalvular leak, arterial/venous fistulae, and congenital heart disease. Click To Read More On Structural Heart Devices Market.
Structural Heart Devices Market Drivers
In 2017, Medtronic plc. received the U.S. Food and Drug Administration (FDA) approval for its new CoreValve Evolut PRO valve for the treatment of severe aortic stenosis in symptomatic patients who are at high or extreme risk for open heart surgery. Moreover, the company has launched CoreValve Evolut PRO valve in the U.S. market in the same year. In 2017, Medtronic plc. received CE Mark for its CoreValve Evolut R 34 mm valve and launched it in European market. CoreValve Evolut R 34 mm is the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. In 2015, Edwards Lifesciences Corporation, an U.S.-based company focused on heart valves and hemodynamic monitoring received U.S. Food and Drug Administration (FDA) approval for its Edwards SAPIEN 3 valve, a transcatheter aortic heart valve used for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis. Furthermore, companies operating in the area are looking to expand product portfolio through inorganic growth. For instance, in 2015, CryoLife, Inc., an U.S.-based medical device company acquired the U.S. based On-X Life Technologies Holdings, Inc., a privately held mechanical heart valve company. CryoLife, Inc. entered in mechanical valve market with On-X Life Technologies Holdings, Inc.’s products with this strategic acquisition.
Structural Heart Devices Market Key Players
Key players in global structural heart devices market include Abbott Laboratories, Medtronic Plc., Edwards Lifesciences Corporation, Boston Scientific Corporation, CryoLife Inc., LivaNova Plc., Cook Group Incorporated, Endologix Inc., and W. L. Gore & Associates, Inc. Key players in the market are focused on strategic merger and acquisition in order to expand its structural heart device product portfolio.
Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1559
For instance, in 2017, Edwards Lifesciences Corporation, an U.S. based medical device manufacturer, acquired Harpoon Medical, Inc. in US$ 100 cash and additional US$150 million in milestone payments over 10 years. With this strategic acquisition Edwards Lifesciences Corporation has widen its offerings with mitral valve repair technology, which is designed to reduce the amount of time required for mitral valve surgery.
Structural Heart Devices Market Regional Analysis
North America is expected to hold a dominant position in global structural heart devices market, owing to continued research for the development of novel product and subsequent launches by major key players present in the region. For Instance, in 2017, Edwards Lifesciences Corporation, an U.S-based company is focusing on Launch of SAPIEN 3 Ultra and CENTERA Valves. SAPIEN 3 Ultra system is a next-generation platform with expandable Axela sheath technology and on-balloon delivery design. This novel product is expected to accelerate the make procedures with less chances of mistakes.
Furthermore, Europe is expected to witness significant growth in structural heart devices market, owing to increasing prevalence of Valvular Heart Disease (VHD) in the region. According to a study published in British Medical Journal (BMJ) in 2017, incidence of VHD was 63.9 per 100 000 person-years, with aortic stenosis (AS; 47.2%), mitral regurgitation (MR; 24.2%) and aortic regurgitation (AR; 18.0%). The study analyzed nationwide hospital data between 2003 and 2010 to reach to this conclusion.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
#Structural Heart Devices Market#Structural Heart Devices Market Size#Structural Heart Devices Market Share#Structural Heart Devices Market Outlook#Structural Heart Devices
0 notes
Text
Structural Heart Devices Market Research Report And Drivers 2019
Structural heart diseases refer to cardiac defects, which are congenital (by birth) in nature and also includes the abnormalities developed in valves and vessels of the heart caused by wear or tear due to some disease. Structural heart diseases is a non-coronary abnormality of heart, which does not affect the blood vessels in the heart. Common structural heart condition includes atrial septal defect, patent foramen oval, ventricular septal defect, paravalvular leak, arterial/venous fistulae, and congenital heart disease.
Structural Heart Devices Market Drivers
In 2017, Medtronic plc. received the U.S. Food and Drug Administration (FDA) approval for its new CoreValve Evolut PRO valve for the treatment of severe aortic stenosis in symptomatic patients who are at high or extreme risk for open heart surgery. Moreover, the company has launched CoreValve Evolut PRO valve in the U.S. market in the same year. In 2017, Medtronic plc. received CE Mark for its CoreValve Evolut R 34 mm valve and launched it in European market. CoreValve Evolut R 34 mm is the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. In 2015, Edwards Lifesciences Corporation, an U.S.-based company focused on heart valves and hemodynamic monitoring received U.S. Food and Drug Administration (FDA) approval for its Edwards SAPIEN 3 valve, a transcatheter aortic heart valve used for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis. Furthermore, companies operating in the area are looking to expand product portfolio through inorganic growth. For instance, in 2015, CryoLife, Inc., an U.S.-based medical device company acquired the U.S. based On-X Life Technologies Holdings, Inc., a privately held mechanical heart valve company. CryoLife, Inc. entered in mechanical valve market with On-X Life Technologies Holdings, Inc.’s products with this strategic acquisition.
Get HOLISTIC Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/1559
Structural Heart Devices Market Regional Analysis
North America is expected to hold a dominant position in global structural heart devices market, owing to continued research for the development of novel product and subsequent launches by major key players present in the region. For Instance, in 2017, Edwards Lifesciences Corporation, an U.S-based company is focusing on Launch of SAPIEN 3 Ultra and CENTERA Valves. SAPIEN 3 Ultra system is a next-generation platform with expandable Axela sheath technology and on-balloon delivery design. This novel product is expected to accelerate the make procedures with less chances of mistakes. Furthermore, Europe is expected to witness significant growth in structural heart devices market, owing to increasing prevalence of Valvular Heart Disease (VHD) in the region. According to a study published in British Medical Journal (BMJ) in 2017, incidence of VHD was 63.9 per 100 000 person-years, with aortic stenosis (AS; 47.2%), mitral regurgitation (MR; 24.2%) and aortic regurgitation (AR; 18.0%). The study analyzed nationwide hospital data between 2003 and 2010 to reach to this conclusion.
Structural Heart Devices Market Restraint
Advanced products such as sutureless heart valve costs significantly higher than earlier available product. For instance, the price of suture less heart valve, aortic manufactured by LivaNova, Plc. is more than US$ 9,000 whereas tissue heart valves manufactured by Medtronic Plc., and Abbott Laboratories costs around US$ 5,000 in the U.S. This almost double price of sutureless device has limited its adoption, which in turn is restraining growth of the market.
Structural Heart Devices Market Key Players
Key players in global structural heart devices market include Abbott Laboratories, Medtronic Plc., Edwards Lifesciences Corporation, Boston Scientific Corporation, CryoLife Inc., LivaNova Plc., Cook Group Incorporated, Endologix Inc., and W. L. Gore & Associates, Inc. Key players in the market are focused on strategic merger and acquisition in order to expand its structural heart device product portfolio. For instance, in 2017, Edwards Lifesciences Corporation, an U.S. based medical device manufacturer, acquired Harpoon Medical, Inc. in US$ 100 cash and additional US$150 million in milestone payments over 10 years. With this strategic acquisition Edwards Lifesciences Corporation has widen its offerings with mitral valve repair technology, which is designed to reduce the amount of time required for mitral valve surgery.
Click To Read More On Structural Heart Devices Market
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email:[email protected]
0 notes